179 related articles for article (PubMed ID: 36812891)
1. An adverse tumor-protective effect of IDO1 inhibition.
Kenski JCN; Huang X; Vredevoogd DW; de Bruijn B; Traets JJH; Ibáñez-Molero S; Schieven SM; van Vliet A; Krijgsman O; Kuilman T; Pozniak J; Loayza-Puch F; Terry AM; Müller J; Logtenberg MEW; de Bruijn M; Levy P; Körner PR; Goding CR; Schumacher TN; Marine JC; Agami R; Peeper DS
Cell Rep Med; 2023 Feb; 4(2):100941. PubMed ID: 36812891
[TBL] [Abstract][Full Text] [Related]
2. Anti-tumour immunity induces aberrant peptide presentation in melanoma.
Bartok O; Pataskar A; Nagel R; Laos M; Goldfarb E; Hayoun D; Levy R; Körner PR; Kreuger IZM; Champagne J; Zaal EA; Bleijerveld OB; Huang X; Kenski J; Wargo J; Brandis A; Levin Y; Mizrahi O; Alon M; Lebon S; Yang W; Nielsen MM; Stern-Ginossar N; Altelaar M; Berkers CR; Geiger T; Peeper DS; Olweus J; Samuels Y; Agami R
Nature; 2021 Feb; 590(7845):332-337. PubMed ID: 33328638
[TBL] [Abstract][Full Text] [Related]
3. GD2 redirected CAR T and activated NK-cell-mediated secretion of IFNγ overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape.
Caforio M; Sorino C; Caruana I; Weber G; Camera A; Cifaldi L; De Angelis B; Del Bufalo F; Vitale A; Goffredo BM; De Vito R; Fruci D; Quintarelli C; Fanciulli M; Locatelli F; Folgiero V
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737337
[TBL] [Abstract][Full Text] [Related]
4. Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy.
Gomes B; Driessens G; Bartlett D; Cai D; Cauwenberghs S; Crosignani S; Dalvie D; Denies S; Dillon CP; Fantin VR; Guo J; Letellier MC; Li W; Maegley K; Marillier R; Miller N; Pirson R; Rabolli V; Ray C; Streiner N; Torti VR; Tsaparikos K; Van den Eynde BJ; Wythes M; Yao LC; Zheng X; Tumang J; Kraus M
Mol Cancer Ther; 2018 Dec; 17(12):2530-2542. PubMed ID: 30232146
[TBL] [Abstract][Full Text] [Related]
5. Clinical Relevance of Serum Kyn/Trp Ratio and Basal and IFNγ-Upregulated IDO1 Expression in Peripheral Monocytes in Early Stage Melanoma.
Meireson A; Ferdinande L; Haspeslagh M; Hennart B; Allorge D; Ost P; Sundahl N; Spaas M; Demeyer A; Brochez L
Front Immunol; 2021; 12():736498. PubMed ID: 34557196
[TBL] [Abstract][Full Text] [Related]
6. Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy.
Fujiwara Y; Kato S; Nesline MK; Conroy JM; DePietro P; Pabla S; Kurzrock R
Cancer Treat Rev; 2022 Nov; 110():102461. PubMed ID: 36058143
[TBL] [Abstract][Full Text] [Related]
7. Interferon-γ induces a tryptophan-selective amino acid transporter in human colonic epithelial cells and mouse dendritic cells.
Bhutia YD; Babu E; Ganapathy V
Biochim Biophys Acta; 2015 Feb; 1848(2):453-62. PubMed ID: 25450809
[TBL] [Abstract][Full Text] [Related]
8. Host cell depletion of tryptophan by IFNγ-induced Indoleamine 2,3-dioxygenase 1 (IDO1) inhibits lysosomal replication of Coxiella burnetii.
Ganesan S; Roy CR
PLoS Pathog; 2019 Aug; 15(8):e1007955. PubMed ID: 31461509
[TBL] [Abstract][Full Text] [Related]
9. Up-regulation of indoleamine 2,3-dioxygenase 1 (IDO1) expression and catalytic activity is associated with immunosuppression and poor prognosis in penile squamous cell carcinoma patients.
Zhou QH; Han H; Lu JB; Liu TY; Huang KB; Deng CZ; Li ZS; Chen JP; Yao K; Qin ZK; Liu ZW; Li YH; Guo SJ; Ye YL; Zhou FJ; Liu RY
Cancer Commun (Lond); 2020 Jan; 40(1):3-15. PubMed ID: 32125093
[TBL] [Abstract][Full Text] [Related]
10. Psychological stress-induced, IDO1-dependent tryptophan catabolism: implications on immunosuppression in mice and humans.
Kiank C; Zeden JP; Drude S; Domanska G; Fusch G; Otten W; Schuett C
PLoS One; 2010 Jul; 5(7):e11825. PubMed ID: 20689575
[TBL] [Abstract][Full Text] [Related]
11. Targeting the IDO1 pathway in cancer: from bench to bedside.
Liu M; Wang X; Wang L; Ma X; Gong Z; Zhang S; Li Y
J Hematol Oncol; 2018 Aug; 11(1):100. PubMed ID: 30068361
[TBL] [Abstract][Full Text] [Related]
12. Promoter Methylation Modulates Indoleamine 2,3-Dioxygenase 1 Induction by Activated T Cells in Human Breast Cancers.
Noonepalle SK; Gu F; Lee EJ; Choi JH; Han Q; Kim J; Ouzounova M; Shull AY; Pei L; Hsu PY; Kolhe R; Shi F; Choi J; Chiou K; Huang TH; Korkaya H; Deng L; Xin HB; Huang S; Thangaraju M; Sreekumar A; Ambs S; Tang SC; Munn DH; Shi H
Cancer Immunol Res; 2017 Apr; 5(4):330-344. PubMed ID: 28264810
[TBL] [Abstract][Full Text] [Related]
13. IDO1 Deficiency Does Not Affect Disease in Mouse Models of Systemic Juvenile Idiopathic Arthritis and Secondary Hemophagocytic Lymphohistiocytosis.
Put K; Brisse E; Avau A; Imbrechts M; Mitera T; Janssens R; Proost P; Fallarino F; Wouters CH; Matthys P
PLoS One; 2016; 11(2):e0150075. PubMed ID: 26914138
[TBL] [Abstract][Full Text] [Related]
14. The signaling function of IDO1 incites the malignant progression of mouse B16 melanoma.
Orecchini E; Belladonna ML; Pallotta MT; Volpi C; Zizi L; Panfili E; Gargaro M; Fallarino F; Rossini S; Suvieri C; Macchiarulo A; Bicciato S; Mondanelli G; Orabona C
Oncoimmunology; 2023; 12(1):2170095. PubMed ID: 36733497
[TBL] [Abstract][Full Text] [Related]
15. The expanding roles of 1-methyl-tryptophan (1-MT): in addition to inhibiting kynurenine production, 1-MT activates the synthesis of melatonin in skin cells.
Moreno AC; Clara RO; Coimbra JB; Júlio AR; Albuquerque RC; Oliveira EM; Maria-Engler SS; Campa A
FEBS J; 2013 Oct; 280(19):4782-92. PubMed ID: 23879623
[TBL] [Abstract][Full Text] [Related]
16. Tumor endothelial cell up-regulation of IDO1 is an immunosuppressive feed-back mechanism that reduces the response to CD40-stimulating immunotherapy.
Georganaki M; Ramachandran M; Tuit S; Núñez NG; Karampatzakis A; Fotaki G; van Hooren L; Huang H; Lugano R; Ulas T; Kaunisto A; Holland EC; Ellmark P; Mangsbo SM; Schultze J; Essand M; Tugues S; Dimberg A
Oncoimmunology; 2020; 9(1):1730538. PubMed ID: 32231867
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia decreases the T helper cell-suppressive capacity of synovial fibroblasts by downregulating IDO1-mediated tryptophan metabolism.
Kaul NC; Mohapatra SR; Adam I; Tucher C; Tretter T; Opitz CA; Lorenz HM; Tykocinski LO
Rheumatology (Oxford); 2020 May; 59(5):1148-1158. PubMed ID: 31846032
[TBL] [Abstract][Full Text] [Related]
18. Investigation of indoleamine 2,3-dioxygenase 1 expression in uveal melanoma.
Liang C; Peng L; Zeng S; Zhao Q; Tang L; Jiang X; Zhang J; Yan N; Chen Y
Exp Eye Res; 2019 Apr; 181():112-119. PubMed ID: 30639792
[TBL] [Abstract][Full Text] [Related]
19. Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond.
Muller AJ; Manfredi MG; Zakharia Y; Prendergast GC
Semin Immunopathol; 2019 Jan; 41(1):41-48. PubMed ID: 30203227
[TBL] [Abstract][Full Text] [Related]
20. Amino acid deprivation links BLIMP-1 to the immunomodulatory enzyme indoleamine 2,3-dioxygenase.
Barnes NA; Stephenson SJ; Tooze RM; Doody GM
J Immunol; 2009 Nov; 183(9):5768-77. PubMed ID: 19828629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
